Paradise Ultrasound Renal Denervation System (Paradise System)
Recor Medical, Inc. · Decision date Aug 13, 2026
What did the FDA approve?
FDA records P220023/S011 as a supplement to PMA P220023, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 13, 2026.
FDA approval order statement
Approval of revision to the protocol for the Post-Approval Study (PAS) referenced above.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 13, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P220023/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Recor Medical, Inc.
- Product code
- QYI
- Decision code
- APPR
- Decision date
- Aug 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Recor Medical, Inc.
- Product code
- QYI
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220023/S009 · Related supplement
ReCor Paradise Catheter
P220023/S011 received
Application receipt date recorded by FDA.
P220023/S012 · Related supplement
Paradise Ultrasound Renal Denervation System (Paradise System); Paradise Catheter
P220023/S011 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P220023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ReCor Paradise CatheterP220023/S009 | Recor Medical, Inc. | PMA supplement | Sep 11, 2025 | FDA |
| Recor Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA |
Explore the linked device profile
Other records with product code QYI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Symplicity Spyral Renal Denervation SystemP220026/S017 | Medtronic, Inc. | PMA supplement | Jul 16, 2026 | FDA |
Symplicity Spyral Renal Denervation CatheterP220026/S016 | Medtronic, Inc. | PMA supplement | Mar 25, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Feb 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Recor Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1049 Elwell Ct., Palo Alto, CA, 94303
Sources and methodology
- Original FDA record: P220023/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


